Core Insights - On September 10, Xiaofang Pharmaceutical experienced a decline of 2.44% with a trading volume of 124 million yuan [1] - The company reported a financing buy-in amount of 12.38 million yuan and a financing repayment of 14.91 million yuan, resulting in a net financing buy of -2.54 million yuan [1] - As of September 10, the total financing and securities lending balance for Xiaofang Pharmaceutical was 137 million yuan, which is 7.20% of its circulating market value, indicating a high level of financing [1] Financing Overview - On September 10, Xiaofang Pharmaceutical had a financing buy-in of 12.38 million yuan, with a current financing balance of 137 million yuan, exceeding the 90th percentile level over the past year [1] - In terms of securities lending, there were no shares repaid or sold on September 10, with a total securities lending balance of 0.00 yuan, also exceeding the 90th percentile level over the past year [1] Company Performance - As of June 30, the number of shareholders for Xiaofang Pharmaceutical was 14,800, a decrease of 22.41% from the previous period, while the average circulating shares per person increased by 28.88% to 2,703 shares [2] - For the first half of 2025, Xiaofang Pharmaceutical achieved a revenue of 270 million yuan, representing a year-on-year growth of 3.06%, and a net profit attributable to shareholders of 121 million yuan, with a year-on-year increase of 1.69% [2] Dividend and Shareholding Structure - Since its A-share listing, Xiaofang Pharmaceutical has distributed a total of 241 million yuan in dividends [3] - As of June 30, 2025, among the top ten circulating shareholders, CITIC Jiantou Rotation Mixed A (003822) ranked as the third-largest shareholder with 439,400 shares, while CITIC Jiantou Selected Mixed A (008347) was the fourth-largest with 298,100 shares, both being new shareholders [3]
小方制药9月10日获融资买入1237.88万元，融资余额1.37亿元